- Correction
- Open access
- Published:
Correction to: Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda
Malaria Journal volume 21, Article number: 37 (2022)
The Original Article was published on 24 December 2021
Correction to: Malaria Journal (2021) 20:484 https://doi.org/10.1186/s12936-021-04021-5
Following publication of the original article [1], it was brought to the publisher’s attention that incorrect details had been provided in the trial registration information of the article.
Where it should read:
-
Trial registration: The trial was also registered with the Pan African Clinical Trial Registry (https://pactr.samrc.ac.za/) with study Trial No. PACTR201811640750761.
It said:
-
Trial registration: The trial was also registered with the ISRCTN registry with study Trial No. PACTR201811640750761.
The original article has been updated accordingly.
Reference
Ebong C, Sserwanga A, Namuganga JF, Kapisi J, Mpimbaza A, Gonahasa S, Asua V, Gudoi S, Kigozi R, Tibenderana J, Bwanika JB, Bosco A, Rubahika D, Kyabayinze D, Opigo J, Rutazana D, Sebikaari G, Belay K, Niang M, Halsey ES, Moriarty LF, Lucchi NW, Svigel Souza SS, Nsobya SL, Kamya MR, Yeka A. Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda. Malar J. 2021;20:484. https://doi.org/10.1186/s12936-021-04021-5.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Ebong, C., Sserwanga, A., Namuganga, J.F. et al. Correction to: Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda. Malar J 21, 37 (2022). https://doi.org/10.1186/s12936-022-04049-1
Published:
DOI: https://doi.org/10.1186/s12936-022-04049-1